CD1d-unrestricted human NKT cells release chemokines upon Fas engagement.

Blood
Martin Giroux, François Denis

Abstract

Attempts at inducing allograft immune privilege by enforced Fas ligand expression have shown accelerated rejection mediated by neutrophils. While it has been proposed that Fas ligand was directly chemotactic toward neutrophils, several lines of evidence argue for an indirect recruitment mechanism. This question was addressed by using in vitro migration assays that used highly purified human leukocyte subsets. Granulocytes did not migrate in response to Fas engagement and required the presence of T cells expressing several natural killer (NK) cell markers. These rare CD8 memory T cells expressed T and NK cell markers and were not restricted to CD1d, showing that they are distinct from conventional natural killer T (NKT) cells. These cells were able to kill both NK-sensitive and -insensitive targets and secreted several CC and CXC chemokines active toward granulocytes, monocytes, and NK cells upon Fas engagement. Chemotactic factor release depended on caspase activity, in the absence of NKT cell apoptosis. The ability of CD1d-unrestricted NKT cells to recruit innate immune system cells might play a role in cancer cell eradication and contribute to inflammatory diseases.

References

Dec 2, 1985·Klinische Wochenschrift·R E SchmidtJ Ritz
Jul 1, 1986·The Journal of Experimental Medicine·R E SchmidtJ Ritz
Feb 1, 1997·Nature Medicine·K SeinoH Yagita
Feb 1, 1997·Annals of Hematology·G D Schmidt-WolfI G Schmidt-Wolf
Feb 1, 1997·Transplantation Proceedings·K SeinoH Yagita
May 1, 1997·Immunology Today·T S Griffith, T A Ferguson
Aug 26, 1998·The Journal of Experimental Medicine·H YamadaK Nomoto
Dec 22, 1999·The Journal of Experimental Medicine·N J KennedyR C Budd
Feb 11, 2000·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·L OttonelloF Dallegri
Feb 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·J M GraysonR Ahmed
Jun 1, 2000·Transplantation·S E TurveyK J Wood
Aug 18, 2000·Cancer Immunology, Immunotherapy : CII·M R VernerisR S Negrin
Sep 28, 2000·Current Opinion in Immunology·W W HancockV Csizmadia
Oct 18, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·E AssarssonB J Chambers
Oct 25, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·T KambayashiH G Ljunggren
Oct 26, 2000·Nature·P H Krammer
Nov 30, 2000·Immunology Today·D I GodfreyA G Baxter
Feb 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·C K BehrensP H Krammer
Mar 7, 2001·Nature Medicine·J O'ConnellF Shanahan
May 5, 2001·Immunity·P J Nelson, A M Krensky
May 26, 2001·Transplantation·B XuC D Platsoucas
Sep 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·J DunneD G Doherty
Nov 21, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·A M HohlbaumA Marshak-Rothstein
Feb 5, 2002·Immunity·Eric J Kunkel, Eugene C Butcher
May 23, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Stephan D GadolaVincenzo Cerundolo
Aug 17, 2002·Current Opinion in Immunology·Karina L McQueen, Peter Parham

❮ Previous
Next ❯

Citations

Jun 10, 2010·Cancer Immunology, Immunotherapy : CII·Mike W HelmsChristopher H Contag
Feb 4, 2009·Journal of Cardiovascular Pharmacology·Andréa Henriques-Pons, Gabriel Melo de Oliveira
Sep 22, 2010·Expert Opinion on Therapeutic Targets·Natasa KovacicAna Marusic
Mar 13, 2016·Cancer Immunology, Immunotherapy : CII·M Virginia GentiliniEloísa Arana
Jun 27, 2007·The American Journal of Pathology·Gabriel Melo de OliveiraAndréa Henriques-Pons
Jun 14, 2005·Expert Opinion on Therapeutic Targets·Ruo-Pan HuangRuochun Huang
Feb 18, 2011·Ultrastructural Pathology·Mohamed A Adly, Mahmoud-Rezk Abdelwahed Hussein
Apr 30, 2014·BioMed Research International·Yongjun JiangHong Shang
Apr 12, 2007·Expert Review of Proteomics·Ruo-Pan Huang
Aug 30, 2020·Andrology·Alenka HodžićBorut Peterlin
Jun 9, 2020·Journal of Clinical Laboratory Analysis·Hui ZhuHonghua Ye

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.